Reviewing Eagleford Energy (OTCMKTS:GRUSF) and Oramed Pharmaceuticals (NASDAQ:ORMP)

Oramed Pharmaceuticals (NASDAQ:ORMP) and Eagleford Energy (OTCMKTS:GRUSF) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.

Earnings and Valuation

This table compares Oramed Pharmaceuticals and Eagleford Energy”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2.00 million	94.14	$64.05 million	$2.59	1.78
Eagleford Energy	$32.43 million	3.52	$3.23 million	N/A	N/A

Oramed Pharmaceuticals has higher earnings, but lower revenue than Eagleford Energy.

Profitability

This table compares Oramed Pharmaceuticals and Eagleford Energy’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%
Eagleford Energy	-1.54%	-2.04%	-0.95%

Analyst Ratings

This is a breakdown of current ratings and price targets for Oramed Pharmaceuticals and Eagleford Energy, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0	1	0	0	2.00
Eagleford Energy	0	0	0	0	0.00

Insider and Institutional Ownership

12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.3% of Eagleford Energy shares are owned by institutional investors. 17.8% of Oramed Pharmaceuticals shares are owned by company insiders. Comparatively, 23.2% of Eagleford Energy shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Oramed Pharmaceuticals beats Eagleford Energy on 5 of the 9 factors compared between the two stocks.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

About Eagleford Energy

Grown Rogue International Inc., together with its subsidiaries, produces and sells cannabis products in the United States. It offers a range of cultivars for consumers, such as indicas, sativas, and hybrids; strain-specific prepackaged flowers; and pre-roll pack products, as well as provides consulting services. The company sells its products through direct-to-retail delivery and third-party delivery, wholesalers, and processors. Grown Rogue International Inc. is headquartered in Medford, Oregon.